



## Current Agreements

### Dealdoc

#### **Marketing and distribution agreement for Brinavess**

Cardiome Pharma  
Aspen Holding

Nov 17 2014

## Marketing and distribution agreement for Brinavess

<b>Companies:</b>	<a href="#">Cardiome Pharma</a> <a href="#">Aspen Holding</a>
<b>Announcement date:</b>	Nov 17 2014
<b>Deal value, US\$m:</b>	n/d

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

### Details

<b>Announcement date:</b>	Nov 17 2014
<b>Industry sectors:</b>	Pharmaceutical
<b>Brand name:</b>	Brinavess
<b>Compound name:</b>	Vernakalant
<b>Exclusivity:</b>	Exclusive
<b>Asset type:</b>	Product
<b>Therapy areas:</b>	Cardiovascular » Arrhythmia » Atrial fibrillation
<b>Technology types:</b>	Small molecules
<b>Deal components:</b>	Distribution Marketing
<b>Stages of development:</b>	Marketed
<b>Geographic focus:</b>	Africa » South Africa

### Financials

<b>Deal value, US\$m:</b>	n/d
---------------------------	-----

### Termsheet

Cardiome Pharma announced that an affiliate of the company has entered into an agreement with Pharmicare Limited, which trades as Aspen Pharmicare and is a part of the Aspen Group, to sell and distribute BRINAVESS (vernakalant intravenous) exclusively in South Africa.

Under the terms of the agreement, Aspen has agreed to specific annual commercial goals for BRINAVESS.

Financial details of the agreement have not been disclosed.

### Press Release

Cardiome Pharma Corp. (COM.TO) Enters Commercialization Agreement With Aspen For BRINAVESS® In South Africa

VANCOUVER, Nov. 17, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that an affiliate of the company has entered into an agreement with Pharmicare Limited, which trades as Aspen Pharmicare and is a part of the Aspen Group, to sell and distribute BRINAVESS® (vernakalant intravenous) exclusively in South Africa. Under the terms of the agreement, Aspen has agreed to specific annual commercial goals for BRINAVESS. Financial details of the agreement have not been disclosed.

"We are pleased to expand our commercial agreement with Aspen to now include BRINAVESS in South Africa," said Karim Lalji, Cardiome's Chief Commercial Officer. "Aspen has proven to be a valuable partner to Cardiome through their commercialization efforts behind AGGRASTAT®. This will be the first country in Africa where BRINAVESS will be launched and we remain committed to making this drug available to all our customers worldwide."

"It is exciting for us to expand our portfolio to now include BRINAVESS alongside Cardiome's AGGRASTAT," said Noel Guliwe, CEO at Aspen Pharmacare, South Africa. "We are looking forward to making it available to all of our hospital customers throughout the country."

In 2014, the South African pharmaceutical market was estimated to be valued at ZAR 30.6.1

References:

Espicom. The Pharmaceutical Market: South Africa, Oct 2014 About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS® (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at [www.cardiome.com](http://www.cardiome.com).

About Aspen

Aspen is a global supplier of branded and generic pharmaceutical products as well as infant milk nutritionals and consumer healthcare products in selected territories. Aspen is the largest pharmaceutical company listed on the South African stock exchange, the JSE Limited, and is one of the top 20 companies listed on this exchange. The Group has 26 manufacturing facilities at 18 sites on 6 continents and approximately 10 000 employees. With its extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced throughout all stages of life, Aspen continues to increase the number of lives benefiting from its products, reaching more than 150 countries across the world.

## **Filing Data**

*Not available.*

## **Contract**

*Not available.*